Navigation Links
Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
Date:3/4/2008

XYOTAX to be reviewed for PS2 first-line non-small cell lung cancer

indication

SEATTLE, March 4 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMEA) for XYOTAX(TM) (paclitaxel poliglumex, CT-2103) for first-line treatment of patients with non-small cell lung cancer (NSCLC) who have ECOG (Eastern Cooperative Oncology Group) performance status 2 (PS2). The application is based on a positive opinion CTI received from the EMEA's Scientific Advice Working Party, which agreed to review the application based on the existing results of the phase III clinical trials of XYOTAX, known as the STELLAR trials.

In the STELLAR 4 trial, single-agent XYOTAX resulted in comparable survival to gemcitabine or vinorelbine in first-line patients and, with the exception of neuropathy known to be associated with taxane therapy, demonstrated significant reduction in several clinically meaningful toxicities, such as severe neutropenia and infection, and in the requirement for transfusions and use of hematopoietic growth factor support. In addition to improved tolerability, XYOTAX offered more convenient administration compared to currently used treatments and a reduction in overall utilization of medical resources compared to gemcitabine or vinorelbine.

The application will be formally reviewed for validation by the end of March. Upon validation, the marketing approval review process begins, which generally takes 15 to 18 months.

"This is an important milestone for CTI and demonstrates our commitment to bring XYOTAX to this underserved group of patients. Currently there are no approved treatments for first-line use in PS2 patients with non-small cell lung cancer. Every day counts when treating patients who may have an average life expectancy of only six months, so quality of life an
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
2. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
3. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
4. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
5. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
6. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
7. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
8. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
9. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
10. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
11. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ... by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), ... of Solta Medical, Inc. (NASDAQ: SLTM ) ...
(Date:1/15/2014)... Mass. , Jan. 15, 2014  Zafgen, Inc., ... unmet needs of severely obese patients, today announced ... beloranib, a selective inhibitor of methionine aminopeptidase 2 ... severe form of genetic obesity.  These results showed ...
(Date:1/14/2014)... , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... for the fourth quarter of 2013 on Monday, February 3, ... release after the close of trading. (Logo: ... call to discuss the operating highlights and financial results for ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... 18 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA),a leading developer ... it,will hold its 2010 Annual Meeting of Shareholders on Thursday, ... meeting will be held concurrently at No. 39,Shangdi Xi Road, Haidian ... St.,John,s, Antigua . All shareholders of record as of ...
... WASHINGTON , June 17 The chairman of ... the U.S. Food and Drug Administration (FDA) over its move toward ... "emergency contraceptive." In a June 17 letter to Dr. ... DiNardo of Galveston - Houston criticized the FDA,s ...
Cached Medicine Technology:Sinovac Schedules 2010 Annual Meeting of Shareholders 2Sinovac Schedules 2010 Annual Meeting of Shareholders 3Pro-Life Chair Voices 'Grave Concern' over FDA Plan to Approve Abortion Drug for 'Emergency Contraception' 2Pro-Life Chair Voices 'Grave Concern' over FDA Plan to Approve Abortion Drug for 'Emergency Contraception' 3Pro-Life Chair Voices 'Grave Concern' over FDA Plan to Approve Abortion Drug for 'Emergency Contraception' 4
(Date:4/24/2014)... Scientists from The University of Manchester have identified a ... them more open to treatment. , The study published ... way for the development of drugs to target cells ... team made the discovery whilst exploring the possible mechanisms ... to treat breast and colon cancer. , Dr Andrew ...
(Date:4/24/2014)... April 24, 2014 ,Take me out to ... slices and kale chips. The more likely culprits include ... , Unfortunately for children who play youth baseball, ... contributing to weight problems, according to researchers at Wake ... current online edition of Childhood Obesity , found ...
(Date:4/24/2014)... corresponding terminology, and the relevance of palliation in ... on randomized controlled trials (RCTs). This is the ... for Quality and Efficiency in Health Care (IQWiG), ... , Together with external experts, IQWiG analysed studies ... cancer, malignant melanoma, and pancreatic cancer. For this ...
(Date:4/24/2014)... awarded one of 30 grants from the National Cancer ... Site in its new National Clinical Trials Network ... of investigators charged with distributing resources in a more ... system reflects recommendations from a 2010 Institute of ... goals:, Faster design, launch, and completion of ...
(Date:4/23/2014)... by Massachusetts General Hospital (MGH) investigators may lead to ... a serious medical problem use of fecal material ... the Clostridium difficile ( C. difficile ) ... the journal Clinical Infectious Diseases , the researchers ... donors unrelated to patients was as successful in curing ...
Breaking Medicine News(10 mins):Health News:Scientists find way to target cells resistant to chemo 2Health News:Take the bat, leave the candy 2Health News:Palliation is rarely a topic in studies on advanced cancer 2Health News:Palliation is rarely a topic in studies on advanced cancer 3Health News:Dartmouth awarded lead role in NCI clinical trials network 2Health News:Dartmouth awarded lead role in NCI clinical trials network 3Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 2Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 3
... theory that contemporary orgasms succor fertility found that women who ... than those that did not. The best way to get ... scientists have ascertained. ,Dr Cathy, from the School of ... age of 32. //The women were asked to go to ...
... sexual intercorse soon after delivery could jeopardize their lives. A ... occured because they indulged in sexual intercourse too soon after ... air embolisms, traveling to the heart and brain.The blood vessels ... upto 4 weeks to return to normal after birth. The ...
... females who are given a choice to select their partners ... research involves the humble fruit fly, but experts believe it ... from the University of Georgia, led by Dr Daniel Promislow, ... in a vial with one virgin female.// Some of the ...
... AIDS will surpass the Black Death as the world's worst ... AIDS do not get life prolonging drugs. The illness has ... 14,000 people are infected each day with HIV, which destroys ... living with AIDS will die, pushing the death toll beyond ...
... out a high number of operations have lower deaths rates ... a scientist at the Institute of Public Health in Cambridge, ... 12 hospitals carrying// out heart surgery on children from 1991 ... carrying out 120 open heart operations on children less than ...
... of countries where leprosy is still a health problem need ... curable disease, the World Health Organization (WHO) has said. Partners ... meeting in Brazil for their annual meeting. Brazil is one ... major public health issue. The others are India, Madagascar, Mozambique, ...
Cached Medicine News:
... a biocompatible, flexible, one-piece artificial cornea (keratoprosthesis) ... native cornea., ,The World Health Organisation (WHO) ... 10 million people worldwide, however only 100,000 ... shortfall is due to a combination of ...
PDA application providing complex evaluation and management coding rule interactive templates....
Provides access via PDA to determine whether imaging examinations are necessary based on symptons and which studies will generate the most information....
PDA-version of the leading portable drug reference....
Medicine Products: